GenSight Biologics   Report issue

For profit Phase 2 Phase 3
Founded: Paris France (2012)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2014
NCT02064569
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

GenSight Biologics

Active Ingredients

Drugs in Phase 3 Trials (1)

gs010 (6 trials)

Drugs in Phase 2 Trials (1)

gs030-dp (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Optic Atrophy, Hereditary, Leber (Phase 3)

Optic Nerve Diseases (Phase 3)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 2